Effect of Exercise and Respiratory Training on Clinical Progression and Survival in Patients with Severe Chronic Pulmonary Hypertension
Open Access
- 9 February 2011
- journal article
- research article
- Published by S. Karger AG in Respiration
- Vol. 81 (5) , 394-401
- https://doi.org/10.1159/000322475
Abstract
Background: Even though specific agents for the treatment of patients with pulmonary hypertension (PH) are available, in PH patients, physical capacity and quality of life (QoL) are often restricted and survival is reduced. Objectives: This study prospectively investigated the long-term effects of respiratory and exercise training in patients with severe chronic PH regarding safety, time to clinical worsening and survival. Methods: Fifty-eight consecutive patients with severe PH on stable disease-targeted medication received exercise and respiratory training in hospital for 3 weeks and continued at home. They were prospectively followed for 24 ± 12 months. Primary endpoints were time to clinical worsening and survival. Adverse events and changes in the 6-min walking test, QoL, WHO functional class and gas exchange were secondary endpoints and were evaluated at baseline and at weeks 3 and 15. Results: All patients tolerated the exercise training well without severe adverse events. In week 15, 6-min walking test results were significantly improved compared to baseline (by 84 ± 49 m, p < 0.001), as well as QoL scores, WHO functional class (from 2.9 ± 0.5 to 2.6 ± 0.6, p < 0.01), peak oxygen consumption (from 12.5 ± 3.0 to 14.6 ± 3.9 ml/min/kg, p < 0.001), heart rate at rest (from 75 ± 12 to 61 ± 18 beats/min, p < 0.001) and maximal workload (from 65 ± 21 to 80 ± 25 W, p < 0.001). Survival at 1 and 2 years was 100 and 95%, respectively. Fifteen events occurred during the follow-up. Conclusion: This study indicates that exercise and respiratory training as add-on to medical treatment may improve exercise capacity and QoL, and that they have a good long-term safety in the described setting.Keywords
This publication has 34 references indexed in Scilit:
- Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analysesEuropean Heart Journal, 2010
- Phosphodiesterase Type 5 Inhibitors for Pulmonary Arterial HypertensionNew England Journal of Medicine, 2009
- Guidelines for the diagnosis and treatment of pulmonary hypertensionEuropean Respiratory Journal, 2009
- Diagnosis and Assessment of Pulmonary Arterial HypertensionJournal of the American College of Cardiology, 2009
- Addition of Sildenafil to Long-Term Intravenous Epoprostenol Therapy in Patients with Pulmonary Arterial HypertensionAnnals of Internal Medicine, 2008
- Sitaxsentan for the Treatment of Pulmonary Arterial HypertensionChest, 2008
- Treprostinil-Based Therapy in the Treatment of Moderate-to-Severe Pulmonary Arterial Hypertension*: Long-term Efficacy and Combination With BosentanChest, 2008
- Combination Therapy and New Types of Agents for Pulmonary Arterial HypertensionClinics in Chest Medicine, 2007
- Goal-oriented treatment and combination therapy for pulmonary arterial hypertensionEuropean Respiratory Journal, 2005
- Primary Pulmonary HypertensionNew England Journal of Medicine, 1997